.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,648,105

« Back to Dashboard

Details for Patent: 8,648,105

Title:Diarylthiohydantoin compounds
Abstract: The present invention relates to diarylthiohydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
Inventor(s): Jung; Michael E. (Los Angeles, CA), Yoo; Dongwon (Los Angeles, CA), Sawyers; Charles L. (New York, NY), Tran; Chris (New York, NY), Wongvipat; John (New York, NY)
Assignee: The Regents of the University of California (Oakland, CA)
Filing Date:Dec 21, 2011
Application Number:13/333,543
Claims:1. A compound having the formula ##STR00148## and pharmaceutically acceptable salts thereof, wherein R.sub.1 and R.sub.2 are independently methyl or, together with the carbon to which they are linked, a cycloalkyl group of 4 to 5 carbon atoms, wherein R.sub.3 is selected from the group consisting of cyanoalkyl and dialkylcarbamoylalkyl, and wherein R.sub.4 is hydrogen or fluorine.

2. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

3. The compound of claim 1, having the formula ##STR00149## wherein R3 is dialkylcarbamoylalkyl and wherein R3 is not dimethylcarbamoylalkyl.

4. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 3 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

5. The pharmaceutical composition of claim 2, having a form selected from the group consisting of a solution, dispersion, suspension, powder, capsule, tablet, pill, time release capsule, time release tablet, and time release pill.

6. A method for treating a cancer, comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, thereby treating the cancer.

7. The method of claim 6, wherein the composition is administered at a dosage of the compound in the range of from about 0.001 mg per kg body weight per day to about 100 mg per kg body weight per day.

8. The method of claim 6, wherein the composition is administered at a dosage of the compound in the range of from about 0.01 mg per kg body weight per day to about 100 mg per kg body weight per day.

9. The method of claim 6, wherein the composition is administered at a dosage of the compound in the range of from about 0.1 mg per kg body weight per day to about 10 mg per kg body weight per day.

10. The method of claim 6, wherein the composition is administered at a dosage of the compound of about 1 mg per kg body weight per day.

11. A method comprising contacting a mammalian cell capable of expressing prostate specific antigen with a sufficient amount of a compound according to claim 1 to interfere with the transcription of prostate specific antigen mRNA.

12. A method, comprising contacting a mammalian cell with a sufficient amount of a compound according to claim 1 to prevent formation of a transcription complex on a prostate specific antigen gene.

13. A method, comprising contacting a mammalian cell with a sufficient amount of a compound according to claim 1 to prevent an androgen receptor protein from complexing with a prostate specific antigen gene.

14. A method, comprising contacting a mammalian cell with a sufficient amount of a compound according to claim 1 to prevent an RNA polymerase II from complexing with a prostate specific antigen gene.

15. A method, comprising contacting a mammalian cell with a sufficient amount of a compound according to claim 1 to prevent nuclear translocation of an androgen receptor protein and/or to destabilize an androgen receptor protein.

16. The method of claim 6, wherein the compound is administered by intravenous injection, by injection into tissue, intraperitoneally, orally, or nasally.

17. The method of claim 6, wherein the cancer is selected from the group consisting of a metastatic cancer, a hormone refractory cancer, prostate cancer, hormone refractory prostate cancer, hormone sensitive prostate cancer, breast cancer, hormone refractory breast cancer, and ovarian cancer.

18. The method of claim 6, further comprising administering a hormone therapy to the subject before the therapeutically effective amount of the compound is administered.

19. A method for treating a cancer, comprising administering a therapeutically effective amount of a compound having the formula ##STR00150## or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, thereby treating the cancer, wherein R.sub.1 and R.sub.2 are independently methyl or, together with the carbon to which they are linked, a cycloalkyl group of 4 to 5 carbon atoms, wherein R.sub.3 is selected from the group consisting of dimethylcarbamoylalkyl and cyanoalkyl, and wherein R.sub.4 is hydrogen or fluorine.

20. The method of claim 19, wherein the cancer is a metastatic cancer.

21. The method of claim 19, wherein the cancer is a hormone refractory cancer.

22. The method of claim 19, wherein the cancer is hormone refractory breast cancer.

23. The method of claim 22, wherein the compound is ##STR00151##

24. The method of claim 22, wherein the compound is ##STR00152##

25. The method of claim 19, further comprising administering a hormone therapy to the subject.

26. The method of claim 25, wherein the hormone therapy is administered prior to the therapeutically effective amount of the compound being administered.

27. The method of claim 25, wherein the cancer is prostate cancer, wherein the hormone therapy is administered prior to the therapeutically effective amount of the compound being administered, and wherein the hormone therapy comprises the administration of bicalutamide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc